CN108939043A - 一种鲨鱼软骨糖蛋白及其抗癌用途 - Google Patents
一种鲨鱼软骨糖蛋白及其抗癌用途 Download PDFInfo
- Publication number
- CN108939043A CN108939043A CN201810982435.9A CN201810982435A CN108939043A CN 108939043 A CN108939043 A CN 108939043A CN 201810982435 A CN201810982435 A CN 201810982435A CN 108939043 A CN108939043 A CN 108939043A
- Authority
- CN
- China
- Prior art keywords
- grams
- shark cartilage
- parts
- pharmaceutical composition
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251730 Chondrichthyes Species 0.000 title claims abstract description 88
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 86
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 42
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 42
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 210000000988 bone and bone Anatomy 0.000 claims description 29
- 244000136948 Ocimum sanctum Species 0.000 claims description 27
- 235000004072 Ocimum sanctum Nutrition 0.000 claims description 27
- 244000183914 Dianthus superbus Species 0.000 claims description 26
- 235000013535 Dianthus superbus Nutrition 0.000 claims description 26
- 241000031023 Amana edulis Species 0.000 claims description 25
- 240000000691 Houttuynia cordata Species 0.000 claims description 25
- 239000009636 Huang Qi Substances 0.000 claims description 25
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 25
- 241000605422 Asparagus asparagoides Species 0.000 claims description 24
- 235000013717 Houttuynia Nutrition 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 24
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 22
- 241000283690 Bos taurus Species 0.000 claims description 20
- 240000008488 Thlaspi arvense Species 0.000 claims description 20
- 235000008214 Thlaspi arvense Nutrition 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 244000025254 Cannabis sativa Species 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 235000019109 Patrinia villosa Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 244000148137 Patrinia villosa Species 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 229940126701 oral medication Drugs 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000234609 Portulaca oleracea Species 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 46
- 201000011510 cancer Diseases 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 25
- 230000035755 proliferation Effects 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 8
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 206010017758 gastric cancer Diseases 0.000 abstract description 4
- 201000007270 liver cancer Diseases 0.000 abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 241000219304 Portulacaceae Species 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 239000000284 extract Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 210000003606 umbilical vein Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 229940036811 bone meal Drugs 0.000 description 4
- 239000002374 bone meal Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000606264 Patrinia Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000020995 raw meat Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000003512 furunculosis Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000283698 Bubalus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000846172 Cremastra appendiculata Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 241001571736 Lysimachia foenum-graecum Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000034042 Mauremys reevesii Species 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001250598 Pleione bulbocodioides Species 0.000 description 1
- 241001457446 Pleione yunnanensis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000758742 Saururaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 241000510764 Villosa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种鲨鱼软骨糖蛋白及其抗癌用途,所述鲨鱼软骨糖蛋白由鲨鱼软骨粉碎后,使用碱水提取后,经盐析、脱游离蛋白和纯化后获得的鲨鱼软骨活性成分,药理实验显示了鲨鱼软骨糖蛋白具有显著的抗血管形成作用,还能抑制皮肤癌、乳腺癌、非小细胞肺癌、肝癌、胃癌、卵巢癌等细胞的增殖,体内实验也显示了优异的抑瘤效果,可广泛应用于癌症的预防和治疗。
Description
技术领域
本发明属于药物领域,具体涉及一种鲨鱼软骨糖蛋白及其抗癌用途。
背景技术
癌症(Cancer),也称恶性肿瘤,是指控制细胞增殖的机制失常而引起的细胞失控性增殖,并局部侵入周围正常组织,甚至经由体内循环系统或淋巴系统转移到身体其他部分的一类疾病。癌症由于在其早期并无明显的临床症状,等发现时往往已处于癌症晚期,往往导致发现时已错过最佳治疗窗口期,使其致死率居高不下,成为世界五大绝症之一。我国是癌症高发地区之一,且近年来癌症的发病率正逐年升高,2014年全国新发癌症约380万例,死亡229万例。截止目前,癌症的确切致病机理仍不清楚,与癌症发病相关的因素主要有外源性因素与内源性因素,其中外源性因素包括生活习惯、环境污染、医源性因素等,内源性因素包括遗传因素、免疫因素、内分泌因素等。癌症的整体发病率虽然性别差别不大,但男性与女性中不同癌症的发病率存在明显区别,由于抽烟及近年来环境污染的加剧,肺癌为男性中发病率最高的癌症,而乳腺癌为女性发病率最高的癌症。
针对癌症的治疗,目前主要包括手术治疗、放疗、化疗等,其中手术治疗在理论上可完全切除癌症组织,从而实现治愈癌症,但由于癌症发现时多已处于癌症晚期,癌细胞已经侵入周围正常组织或随循环系统扩散至身体其他器官,使得无法通过手术完全清楚癌症细胞,并且手术为有创性治疗手段,手术过程中伴随着癌症组织周围循环系统的破坏,一定程度上可能会促进癌细胞的扩散,加之手术所带来的伤口感染、人体免疫系统的破坏等不利影响,造成了手术治疗在癌症治疗中所发挥的作用仍然十分有限。放射治疗是使用辐射杀死癌细胞的方法,但放射治疗由于缺乏靶向性,会造成正常细胞的大面积损伤,影响患者的消化系统,破坏患者的免疫系统,使得患者自身抵御癌症的能力大幅度下降,虽然在现代放射治疗在癌症治疗过程中被广泛采用,但其也仅为权宜之计,并非治疗癌症的理想手段。化疗,全称为化学治疗,是指服用可以杀死癌症细胞的药物,从而用于治疗癌症。化疗药同样存在对正常细胞的损害,但通过化疗药物研究的不断深入,人们正努力通过靶向性给药、开发对正常组织损伤作用更小的药物,以避免化疗过程中对正常组织细胞的损伤,从而能够有效治疗癌症。
上世纪80年代人们发现了鲨鱼软骨具有抑制血管生成的作用,因此逐渐将其应用于癌症的预防与治疗,但其整体治疗效果仍不理想。近年来人们先后研究了鲨鱼软骨提取物、鲨鱼软骨素、鲨鱼软骨血管生产抑制因子的抗癌效果,均未获得突破性的进展,甚至一度出现了鲨鱼软骨不具有抗癌效果的观点。
本发明发明人在充分调研现有技术的基础上,通过大量实验,由鲨鱼软骨中分离得到了一种鲨鱼软骨糖蛋白,药理实验显示其相对于鲨鱼软骨的粗提取具有优异的抑制血管形成和促进癌细胞凋亡的效果,可用于癌症的预防和治疗。
发明内容
本发明的目的是提供一种鲨鱼软骨糖蛋白在制备抗癌药物中的用途。
优选的,所述鲨鱼软骨糖蛋白由以下方法制备得到:
(1)鲨鱼软骨粉碎后过10-30目筛,得鲨鱼软骨颗粒;
(2)鲨鱼软骨颗粒加入3-8倍的纯净水后使用NaOH调节pH为10-13,加热至50-70℃,浸泡3-10小时后过滤,滤液备用,滤渣重复浸提1-2次,滤液合并;
(3)滤液经盐析后,使用Sevage法去除游离蛋白质,再经透析和DEAE-C32阴离子交互树脂柱层析后冷冻干燥制得鲨鱼软骨糖蛋白。
本发明的再一个目的是提供一种抗癌药物组合物,其包含鲨鱼软骨糖蛋白或鲨鱼软骨。
优选的,所述抗癌药物组合物还包含龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香。
优选的,所述抗癌药物组合物由鲨鱼软骨5-10份、龟板2-5份、鲍鱼壳1-3份、小苏打1-3份、蛤蜊壳1-3份、马齿苋3-8份、牛骨粉8-15份、土茯苓2-5份、山慈菇5-10份、败酱草2-5份、鱼腥草1-3份、黄芪1-3份、瞿麦1-3份、零陵香1-3份制成。
更优选的,所述抗癌药物组合物由鲨鱼软骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克、零陵香10克制成。
本发明药物组合物中:
鲨鱼软骨:具有抗肿瘤、祛风湿、止痛、止泻等多重功效,常用于风湿性关节炎、头痛、腹泻等症的治疗。
龟板:为龟科动物chinemys reevesii的腹甲及背甲,主要分布于浙江、湖北、湖南等地,龟板味咸甘、性平,具有滋阴、潜阳、补肾、健骨的作用,常用于骨蒸劳热、潮热、盗汗、崩漏、遗精、带下、骨痿、吐血等症的治疗,现代药理研究表明龟板具有提高机体免疫功能、抗肿瘤等作用。
鲍鱼壳:又称石决明,为是珍贵的药材,具有清热平肝、滋阴壮阳的功效,鲍鱼以及鲍鱼壳包含丰富的蛋白质,鲍鱼壳本身的营养价值也非常高,鲍鱼壳入药可以治疗高血压、眩晕、目暴肿疼痛等多种疾病,由鲍鱼壳中提炼出的甲壳素,还可用于胃及十二指肠溃疡、胃酸过多等症的治疗。
小苏打:即碳酸氢钠,化学式为NaHCO3,小苏打溶液呈碱性,医学上外用可消毒杀菌,口服可用于治疗胃酸过多的治疗,静脉给药还可用于纠正酸中毒。现代病理研究表明肿瘤内部为酸性环境,服用小苏打,可以打破肿瘤组织酸性环境,抑制肿瘤细胞增殖。
蛤蜊壳:蛤蜊味咸,性寒,具有滋阴润燥、利尿消肿、软坚散结作用。《本草经疏》中记载:″蛤蜊其性滋润而助津液,故能润五脏、止消渴,开胃也。咸能入血软坚,故主妇人血块及老癖为寒热也。″蛤蜊对肉瘤和腹水瘤都有抑制作用和缓解作用。蛤蜊壳味咸,性寒凉,可以入肺经和肾经以及肝经,能清热,也能化痰利湿,还能软坚,常用于治疗胃痛、饮喘咳、水气浮肿、小便不利、带下痈肿和烫伤等。著名方药蛤蜊散即是将蛤蜊壳洗净后置炭火烧焙,用于痰火喘咳的治疗。
马齿苋:为马齿苋科植物马齿苋的干燥地上部分,味酸、性寒,归肝、大肠经,有清热利湿、解毒消肿、消炎、止渴、利尿的效果,常用于热毒血痢、痈肿疔疮、湿疹、丹毒、蛇虫咬伤、便血、崩漏等症的治疗。
牛骨粉:为牛科野牛属动物黄牛或水牛属动物水牛的骨骼,味甘、性温,具有蠲痹、截疟、敛疮等功效,常用于关节炎、泻痢、疟疾、疳疮等症的治疗。骨中所含的骨髓自古就有″补精髓、壮筋骨、延年益寿″的记载,古籍《寿世真元》认为:骨髓″专补虚损,活血荣筋,润泽肌肤,返老还童″,是抗衰老的造血器官,能增进人体的造血机能,提高肌体免疫力,含有人体所需的全部营养精华,有促进儿童大脑发育、健脑增智之功效的卵磷脂;有滋润皮肤、美容养颜、防衰老的骨胶原(多种氨基酸)、粘多糖和多种蛋白肽等。牛骨还储藏着丰富的营养,其蛋白质、铁质、钠和产生的能量远远高于鲜肉,蛋白质含量高出奶粉23%,是猪肉的两倍,高出牛肉61%,是鸡蛋的1倍多,磷、钙含量更是其它食物所不能比拟的。尤其难得的是,牛骨的营养成分比植物蛋白更易为人体所吸收。
土茯苓:为百合科植物光叶菝葜的干燥根茎,味甘、淡,性平。有解毒除湿、同理关节的功效,常用于梅毒及汞中毒所致的肢体拘挛、筋骨疼痛、湿热淋浊、带下、痈肿、瘰疬、疥癣等症的治疗。
山慈菇:为兰科植物杜鹃兰、独蒜兰或云南独蒜兰的干燥假鳞茎,味甘、微辛,性凉,归肝、脾经。具有清热解毒,消痈散结的功效,常用于痈肿疔毒、瘰疬病核、蛇虫咬伤等症的治疗。
败酱草:为败酱科植物白花败酱的干燥全草,味辛、苦,性凉,归肝、胃、大肠经,具有清热解毒、祛痰排脓的功效,常用于肠痈、肺痈、痢疾、痈肿疔疮等症的治疗。
鱼腥草:为三白草科植物蕺菜的干燥地上部分,味辛,性寒凉,归肺经。具有清热解毒、消肿排脓疗疮、利尿除湿、清热止痢、健胃消食的功效,可用于治疗肺脓溃疡、肺热咳喘、热痢热淋、水肿、脚气、尿路感染、白带过多、痈肿疮毒等症,现代药理研究表明,鱼腥草还具有抗菌、抗病毒、提高机体免疫力,利尿等作用。临床实践证明鱼腥草对于上呼吸道感染、支气管炎、肺炎、慢性气管炎、慢性宫颈炎、百日咳等均有较好的疗效,对急性结膜炎、尿路感染等也有一定疗效。
黄芪:为豆科植物蒙古黄芪的根,味甘、性温,归肺、脾、肝、肾经。具有补气固表、托毒排脓、利尿、生肌的功效,常用于气虚乏力、久泻脱肛、自汗、水肿、子宫脱垂、糖尿病、创口久不愈合等症的治疗。
瞿麦:为石竹科植物瞿麦的干燥地上部分,味苦,性寒,归心、小肠经。具有利尿通淋、活血通经的功效,常用于热淋、血淋、石淋、小便不通、淋沥涩痛、经闭等症的治疗。
零陵香:又称熏草、铃铃香,为报春花科植物灵香草的带根全草,味辛甘,性温,归足太阴、阳明经,具有祛风寒、辟秽浊的功效,常用于治疗伤寒、感冒头痛、胸腹胀满、不利、遗精、鼻塞、牙痛等症。
本发明抗癌药物组合物为口服药物组合物或局部施用药物组合物。
优选的,所述口服药物组合物为为片剂、胶囊剂、颗粒剂、丸剂、散剂、汤剂;所述局部施用药物组合物为外敷膏剂。
本发明的再一个目的是提供一种口服抗癌药物组合物的制备方法,包括以下步骤:
鲨鱼软骨糖蛋白添加药学上可接受的辅料后,按照本领域常规方法制得口服抗癌药物组合物。、
或按照以下步骤制备的到:
(1)将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香各自粉碎成20目颗粒后混匀;
(2)将步骤(1)所得混合颗粒加入5倍的纯净水后使用NaOH调节pH为12,加热至60℃,浸泡5小时后过滤,滤液备用,滤渣重复浸提2次,滤液合并,减压浓缩为25℃时密度为1.02-1.05的浸膏;
(3)步骤(2)所的浸膏药学上可接受的辅料后按照本领域常规方法制备得到口服抗癌药物组合物。
本发明的再一个目的是提供一种抗癌药物组合物外敷膏剂的制备方法,包括以下步骤:
(1)将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香粉碎成150-200目颗粒;
(2)将鱼腥草、零陵香、山慈菇、败酱草颗粒使用海盐泡水48小时,使用时,使用该水将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、黄芪、瞿麦颗粒调成药膏,即得外敷膏剂。
本发明的再一个目的提供一种包含所述鲨鱼软骨糖蛋白或鲨鱼软骨的组合物在制备抗癌药物中的用途,所述鲨鱼软骨糖蛋白由以下方法制备得到:
(1)鲨鱼软骨粉碎后过10-30目筛,得鲨鱼软骨颗粒;
(2)鲨鱼软骨颗粒加入3-8倍的纯净水后使用NaOH调节pH为10-13,加热至50-70℃,浸泡3-10小时后过滤,滤液备用,滤渣重复浸提1-2次,滤液合并;
(3)滤液经盐析后,使用Sevage法去除游离蛋白质,再经透析和DEAE-C32阴离子交互树脂柱层析后冷冻干燥制得鲨鱼软骨糖蛋白。
优选的,所述抗癌药物组合物还包含龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香。
优选的,所述抗癌药物组合物由鲨鱼软骨5-10份、龟板2-5份、鲍鱼壳1-3份、小苏打1-3份、蛤蜊壳1-3份、马齿苋3-8份、牛骨粉8-15份、土茯苓2-5份、山慈菇5-10份、败酱草2-5份、鱼腥草1-3份、黄芪1-3份、瞿麦1-3份、零陵香1-3份制成。
更优选的,所述抗癌药物组合物由鲨鱼软骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克、零陵香10克制成。
本发明有益效果
本发明分离得到了鲨鱼软骨中的鲨鱼软骨糖蛋白,体外实验显示鲨鱼软骨糖蛋白具有抑制人脐静脉内皮细胞增殖的作用,还可以抑制皮肤癌细胞、乳腺癌细胞、肝癌细胞、肺癌细胞、胃癌细胞的增殖。
本发明在发现鲨鱼软骨糖蛋白可以有效抗血管形成,诱导癌细胞凋亡的基础上,还提出了一种抗癌药物组合物,所述抗癌药物组合物通过鲨鱼软骨糖蛋白或鲨鱼软骨与其他成分配伍使用,取得了相对于鲨鱼软骨糖蛋白更为优异的抗血管形成和诱导癌细胞凋亡的效果,尤其是零陵香的加入,使得本发明的药物组合物取得了意料不到的抗癌效果。
具体实施方式
在下文中更详细地描述了本发明以有助于对本发明的理解。
实施例1:一种鲨鱼软骨糖蛋白
所述鲨鱼软骨糖蛋白按照以下方法制备:
(1)鲨鱼软骨200g,粉碎后过20目筛,得鲨鱼软骨颗粒;
(2)鲨鱼软骨颗粒加入5倍的纯净水后使用NaOH调节pH为12,加热至60℃,浸泡5小时后过滤,滤液备用,滤渣重复浸提2次,滤液合并;
(3)滤液经盐析后,使用Sevage法去除游离蛋白质,再经透析和DEAE-C32阴离子交互树脂柱层析后,冷冻干燥制得鲨鱼软骨糖蛋白5.6g。
实施例2:一种抗癌片剂
鲨鱼软骨糖蛋白30克、微晶纤维素230g、羟丙基纤维素25g、羧甲基淀粉钠15g、硬脂酸镁适量,按照以下方法制备:
鲨鱼软骨糖蛋白粉碎过60目筛,添加微晶纤维素后使用羟丙基纤维素制软才,过14目筛制粒,干燥后过12目筛整粒,加入羧甲基淀粉钠及硬脂酸镁后混匀,压片得抗癌片剂1000片。
实施例3:一种抗癌外敷膏剂
鲨鱼软骨糖蛋白3克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克、零陵香10克,按照以下方法制备:
(1)将龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香粉碎成180目颗粒;
(2)将鱼腥草、零陵香、山慈菇、败酱草颗粒使用海盐泡水48小时,使用时,使用该水将鲨鱼软骨糖蛋白与龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、黄芪、瞿麦颗粒调成药膏,即得外敷膏剂。
实施例4:一种抗癌外敷膏剂
鲨鱼软骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克、零陵香10克,按照以下方法制备:
(1)将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香粉碎成180目颗粒;
(2)将鱼腥草、零陵香、山慈菇、败酱草颗粒使用海盐泡水48小时,使用时,使用该水将鲨鱼软骨糖蛋白与龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、黄芪、瞿麦颗粒调成药膏,即得外敷膏剂。
实施例5:一种抗癌胶囊剂
鲨鱼软骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克、零陵香10克,按照以下方法制备:
(1)将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香各自粉碎成20目颗粒后混匀;
(2)将步骤(1)所得混合颗粒加入5倍的纯净水后使用NaOH调节pH为12,加热至60℃,浸泡5小时后过滤,滤液备用,滤渣重复浸提2次,滤液合并,减压浓缩为25℃时密度为1.02-1.05的浸膏;
(3)步骤(2)所的浸膏添加微晶纤维素后制软材,过14目筛制粒,干燥后过12目筛整粒,添加适量硬脂酸镁后灌装于明胶胶囊壳,制得抗癌胶囊100粒。
对比例1:一种抗癌药物组合物
鲨鱼软骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克,按照实施例4步骤制备得到外敷膏剂。
对比例2:一种抗癌药物组合物
鲨鱼软骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克,按照实施例5步骤制备得到浸膏。
效果例1本发明药物组合物的抗血管形成作用
1.1实验药物
实施例1鲨鱼软骨糖蛋白使用灭菌PBS配制为200mg/L的悬浮液、实施例5步骤(2)所得浸膏、对比例2浸膏均使用灭菌PBS配置为5g生药/mL的混悬液。
1.2实验方法
新鲜人脐带15cm,使用灭菌PBS清洗脐带外表并冲洗脐带静脉至无残血,结扎脐带一端,在脐带开口端静脉内灌注2.5g/L胰蛋白酶后,消化20min,期间每隔3分钟摇晃脐带一次,消化完成后将消化液注入50mL无菌离心管中,再使用灭菌PBS冲洗脐静脉2次,冲洗液同样注入无菌离心管中,离心,弃上清,加入灭菌PBS30mL后,吹打均匀后再次离心,弃上清,沉淀加入含10%新生牛血清的DMEM培养基,加入24孔板,放置于37℃、5%湿度的CO2培养箱中培养24h,更换含10%新生牛血清的DMEM培养基后继续培养24小时,得原代分离的人脐静脉内皮细胞。
原代分离的人脐静脉内皮细胞用0.05%的胰酶消化后,以2×104个/mL的密度接种于96孔板,200μl/孔,共4组,具体为空白组、鲨鱼软骨糖蛋白组、实施例5组、对比例2组,每组设置3个平行孔,放置于37℃、5%湿度的CO2培养箱培养24h,加入测试药物50μl/孔,具体的为:空白组加入PBS、鲨鱼软骨糖蛋白组加入鲨鱼软骨糖蛋白200mg/L的混悬液,实施例5组加入5g生药/mL的实施例5所得浸膏的混悬液、对比例2组添加加入5g生药/mL的对比例2所得浸膏的混悬液。继续培养24h后,弃去上清,加入5mg/ml MTT试剂20μL和200μL DMSO,3h后使用酶标仪测试570nm吸光度值,计算各组的人脐静脉内皮细胞增殖抑制率,具体结果见表1,其中:
增殖抑制率=(对照组吸光度值-实验组吸光度值)/对照组吸光度值×100%。
1.3实验结果
表1本发明药物组合物对人脐静脉内皮细胞的增殖抑制作用
表1实验结果显示,不含零陵香的对比例2组药物组合物的提取物浸膏也显示了一定的抑制人脐静脉内皮细胞增殖的效果,而鲨鱼软骨糖蛋白则具有明显的人脐静脉内皮细胞的增殖抑制效果,本发明实施例5组药物组合物则显示了更为优异的人脐静脉内皮细胞的增殖抑制效果,其抑制率约为单独鲨鱼软骨糖蛋白的1.7倍,为不含零陵香的对比例2组抑制率的2.7倍,该实验结果也提示了零陵香的加入显著增强含鲨鱼软骨的药物组合物的的抗血管形成效果。
效果例2:本发明药物组合物对肿瘤细胞的生长抑制效果
2.1实验药物
实施例1鲨鱼软骨糖蛋白使用灭菌PBS配制为200mg/L的悬浮液、实施例5步骤(2)所得浸膏、对比例2浸膏均使用灭菌PBS配置为5g生药/mL的混悬液。
2.2实验方法
细胞系:HS-4(人皮肤癌细胞)、MCF-7(人乳腺癌细胞)、A549(人肺腺癌细胞)、HepG2(人肝癌细胞)、MGC80-3(人胃癌细胞)
取对数生长期的以上细胞系,以2×104个/mL的密度接种于96孔板,200μl/孔,共4组,具体为空白组、鲨鱼软骨糖蛋白组、实施例5组、对比例2组,每组设置3个平行孔,放置于37℃、5%湿度的CO2培养箱培养24h,加入测试药物50μl/孔,具体的为:空白组加入PBS、鲨鱼软骨糖蛋白组加入鲨鱼软骨糖蛋白200mg/L的混悬液,实施例5组加入5g生药/mL的实施例5所得浸膏的混悬液、对比例2组添加加入5g生药/mL的对比例2所得浸膏的混悬液。继续培养24h后,弃去上清,加入5mg/ml MTT试剂20μL和200μL DMSO,3h后使用酶标仪测试570nm吸光度值,计算各组的肿瘤细胞增殖抑制率,具体结果见表2,其中:
增殖抑制率=(对照组吸光度值-实验组吸光度值)/对照组吸光度值×100%。
2.3实验结果
表2本发明药物组合物对肿瘤细胞的增殖抑制作用
表2实验结果显示了鲨鱼软骨糖蛋白及本发明实施例5组药物组合物的提取物浸膏针对于人皮肤癌细胞、人乳腺癌细胞、人肺腺癌细胞、人肝癌细胞和人胃癌细胞均显示了明显的增殖抑制作用,尤其是针对人皮肤癌细胞、人乳腺癌细胞、人肺腺癌细胞增殖抑制效果更为明显,表明了本发明药物组合物具有优异肿瘤细胞增殖抑制效果,而其他组成成分相同,但不含零陵香的对比例2组药物组合物针对于各肿瘤细胞的增殖抑制作用相对于实施例5组均明显降低,该实验结果也证明了零陵香的加入可明显提高含鲨鱼软骨的药物组合的抑制肿瘤细胞的增殖作用。
效果例3:本发明外敷膏剂对荷瘤小鼠的治疗效果
3.1实验药物:
实施例4外敷膏剂。
3.2实验方法
雄性Balb/c小鼠20只,体重20±2g,适应性饲养1天后,酒精消毒小鼠前肢腋下,以5×104浓度接种小鼠黑色素瘤细胞B16 0.2mL,接种10天后挑选接种成功、且瘤体积大致相当的小鼠10只,随机分为2组,具体为模型组、实施例4组,每组5只,其中模型组使用生理盐水涂敷肿瘤部位,实施例4组将实施例4组制备得到的外敷膏剂涂敷于肿瘤部位,每天一次,涂敷完成后以纱布包裹涂敷部位,避免小鼠舔舐造成的涂敷物掉落,每次涂敷前清除上次涂敷的药渣,连续施用15天,末次给药2h后,记录各组存活小鼠只数,小鼠断颈处死,剥离肿瘤组织并称重,计算抑瘤率,具体实验见表3,其中:
抑瘤率=(模型组瘤重-实验组瘤重)/模型组瘤重×100%。
3.3实验结果
应用统计软件SPSS的多因素方差分析模块进行数据分析,P<0.05表示差异有统计学意义。
表3实验结果显示了实验结束时模型组5只小鼠中已死亡两只,而实施例4组小鼠5只小鼠全部存活,荷瘤小鼠肿瘤的生长也受到了明显抑制,抑瘤率超过了50%,显示了优异的体内抗肿瘤效果。
表3本发明外敷膏剂对荷瘤小鼠的治疗效果
**,与模型组相比P<0.01。
以上描述了本发明优选实施方式,然其并非用以限定本发明。本领域技术人员对在此公开的实施方案可进行并不偏离本发明范畴和精神的改进和变化。
Claims (10)
1.鲨鱼软骨糖蛋白在制备抗癌药物中的用途。
2.根据权利要求1所述的用途,其特征在于所述鲨鱼软骨糖蛋白由以下方法制备得到:
(1)鲨鱼软骨粉碎后过10-30目筛,的鲨鱼软骨颗粒;
(2)鲨鱼软骨颗粒加入3-8倍的纯净水后使用NaOH调节pH为10-13,加热至50-70℃,浸泡3-10小时后过滤,滤液备用,滤渣重复浸提1-2次,滤液合并;
(3)滤液经盐析后,使用Sevage法去除游离蛋白质,再经透析和DEAE-C32阴离子交互树脂柱层析后制得。
3.一种抗癌药物组合物,其特征在于包含鲨鱼软骨糖蛋白或鲨鱼软骨。
4.根据权利要求3所述的抗癌药物组合物,其特征在于还包含龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香。
5.根据权利要求4所述的抗癌药物组合物,其特征在于:所述药物组合物由鲨鱼软骨5-10份、龟板2-5份、鲍鱼壳1-3份、小苏打1-3份、蛤蜊壳1-3份、马齿苋3-8份、牛骨粉8-15份、土茯苓2-5份、山慈菇5-10份、败酱草2-5份、鱼腥草1-3份、黄芪1-3份、瞿麦1-3份、零陵香1-3份制成。
6.根据权利要求5所述的抗癌药物组合物,其特征在于:所述药物组合物由鲨鱼骨80克、龟板30克、鲍鱼壳20克、小苏打20克、蛤蜊壳20克、马齿苋50克、牛骨粉100克、土茯苓30克、山慈菇80克、败酱草30克、鱼腥草10克、黄芪10克、瞿麦10克、零陵香10克制成。
7.权利要求4-6任一项所述的抗癌药物组合物,其特征在于:所述药物组合物为口服药物组合物或局部施用药物组合物。
8.根据权利要求7所述的抗癌药物组合物,其特征在于:所述口服药物组合物为片剂、胶囊剂、颗粒剂、丸剂、散剂、汤剂;所述局部施用药物组合物为外敷膏剂。
9.根据权利要求8所述的抗癌药物组合物,其特征在于:所述外敷膏剂通过以下方法制备得到:
(1)将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、山慈菇、败酱草、鱼腥草、黄芪、瞿麦、零陵香粉碎成150-200目颗粒;
(2)将鱼腥草、零陵香、山慈菇、败酱草颗粒使用海盐泡水48小时,使用时,使用该水将鲨鱼软骨、龟板、鲍鱼壳、小苏打、蛤蜊壳、马齿苋、牛骨粉、土茯苓、黄芪、瞿麦颗粒调成药膏,即得外敷膏剂。
10.权利要求4-9任一项所述的抗癌药物组合物在制备抗癌药物组合物中的用途。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810982435.9A CN108939043A (zh) | 2018-08-27 | 2018-08-27 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
| PCT/CN2019/086298 WO2020042665A1 (zh) | 2018-08-27 | 2019-05-09 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810982435.9A CN108939043A (zh) | 2018-08-27 | 2018-08-27 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108939043A true CN108939043A (zh) | 2018-12-07 |
Family
ID=64473245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810982435.9A Pending CN108939043A (zh) | 2018-08-27 | 2018-08-27 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108939043A (zh) |
| WO (1) | WO2020042665A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020042665A1 (zh) * | 2018-08-27 | 2020-03-05 | 车路平 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
| CN113116930A (zh) * | 2020-01-10 | 2021-07-16 | 姚明波 | 一种抗癌药物及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200423951A (en) * | 2002-11-13 | 2004-11-16 | Ming-Chung Wong | Method of preparing anti-angiogenic drug from cartilage and chondrocytes and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101819181B (zh) * | 2010-04-09 | 2012-07-04 | 新疆三叶管道技术有限责任公司 | 管道缺陷漏磁检测装置 |
| CN108939043A (zh) * | 2018-08-27 | 2018-12-07 | 车路平 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
-
2018
- 2018-08-27 CN CN201810982435.9A patent/CN108939043A/zh active Pending
-
2019
- 2019-05-09 WO PCT/CN2019/086298 patent/WO2020042665A1/zh not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200423951A (en) * | 2002-11-13 | 2004-11-16 | Ming-Chung Wong | Method of preparing anti-angiogenic drug from cartilage and chondrocytes and methods of use |
Non-Patent Citations (8)
| Title |
|---|
| LIZA MERLY,ET AL: "Collagen type II, alpha 1 protein: A bioactive component of shark cartilage", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
| 吴复苍: "《常见病遣方用药规律》", 30 October 2015, 人民军医出版社 * |
| 周德生: "《本草利害释义》", 31 March 2012, 太原科学技术出版社 * |
| 张铂等: "海洋抗肿瘤活性蛋白与多肽的研究进展", 《中国海洋药物》 * |
| 方旭波等: "鱿鱼硫酸软骨素糖蛋白的分离纯化和鉴定", 《中国食品学报》 * |
| 柏晶妹: "《实用临床护理学》", 31 March 2018, 云南科技出版社 * |
| 蔡平等: "鲨鱼软骨血管形成抑制因子研究与开发现状", 《中国海洋药物》 * |
| 郑兰红等: "鲨鱼软骨血管生成抑制因子的国内外研究进展", 《2007医学前沿论坛暨第十届全国肿瘤药理与化疗学术会议论文集》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020042665A1 (zh) * | 2018-08-27 | 2020-03-05 | 车路平 | 一种鲨鱼软骨糖蛋白及其抗癌用途 |
| CN113116930A (zh) * | 2020-01-10 | 2021-07-16 | 姚明波 | 一种抗癌药物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020042665A1 (zh) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104479964A (zh) | 一种黄秋葵、菌、藻保健酒及其制备方法 | |
| CN108939043A (zh) | 一种鲨鱼软骨糖蛋白及其抗癌用途 | |
| CN103877486B (zh) | 用于促升放化疗后白细胞数量的药物及其制备方法 | |
| CN105535495B (zh) | 一种培元固本治疗食管癌的中药组合物及制备方法 | |
| CN108186899A (zh) | 一种治疗肿瘤的中药组合物及其制备方法与应用 | |
| CN104162093A (zh) | 治疗乳腺癌的中药制剂及其制备方法 | |
| CN116942766A (zh) | 一种药食同源组合物及其制备方法 | |
| CN104258260B (zh) | 一种肉苁蓉醇提取物、制备方法及其用途 | |
| WO2018171672A1 (zh) | 一种抗癌药物组合物及其用途 | |
| CN108186921B (zh) | 一种抗肿瘤的含硒中药组合物及其制备方法 | |
| CN108355052B (zh) | 一种治疗放化疗后白细胞降低的药物及其制备方法与应用 | |
| CN105688171B (zh) | 一种雏鸡用饲料添加剂及其制备方法 | |
| CN108783443A (zh) | 一种用于脏腑调理的片剂及其制备方法 | |
| CN108042588A (zh) | 一种洋参灵芝菇散 | |
| CN106177391A (zh) | 一种治疗癌症的药物组合物及其制备方法 | |
| CN105617007A (zh) | 一种治疗肿瘤的中药及其制备方法 | |
| CN106668494A (zh) | 回族中药芪根胃癌消颗粒及其制备方法 | |
| CN104784509A (zh) | 用于提高恶性肿瘤患者免疫功能的中药制剂 | |
| CN103816468B (zh) | 一种治疗胃癌的胶囊及其制备方法 | |
| CN118340834A (zh) | 一种防治心血管疾病兼证便秘的中药组合物 | |
| CN114010753A (zh) | 一种活络镇痛的中药组合物及其制备方法 | |
| CN104398627A (zh) | 食管癌以毒攻毒药剂及制备方法 | |
| CN112426491A (zh) | 一种治疗恶性黑色素瘤的中药组合物 | |
| CN113144079A (zh) | 一种用于防治流行性感冒的中药制剂及其制备方法 | |
| CN112294915A (zh) | 一种治疗肺气肿的药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 266071 Unit 103, No. 1, No. 2, Xiuzhan Road, Southern District, Qingdao City, Shandong Province Applicant after: Che Luping Address before: Room 01116, Building 1, Chengshousi Road, Fengtai District, Beijing Applicant before: Che Luping |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181207 |
|
| RJ01 | Rejection of invention patent application after publication |